Parmax Pharma will hold a board meeting on June 8, 2026 to evaluate proposals for raising funds through the issuance of eligible securities. The meeting, scheduled to take place at the company's registered office in Rajkot, Gujarat, will consider raising capital via equity shares or equity-linked instruments through a preferential issue on a private placement basis or other methods.

The Board of Directors will discuss and consider the fund-raising proposals, subject to necessary regulatory and statutory approvals, including shareholder consent. Ancillary actions required to facilitate the fund raising in accordance with the Companies Act, 2013, and SEBI regulations will also be reviewed.

Extraordinary General Meeting

In addition to the fund-raising discussion, the board will approve the draft notice and decide on the day, date, and place for an Extraordinary General Meeting (EGM). The EGM is intended to seek shareholder approval for the aforementioned proposals.

Trading Window Closure

Pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the company's securities by designated persons will remain closed. The closure period is effective from June 3, 2026, and will continue until 48 hours after the conclusion of the board meeting on June 8, 2026. Directors, connected persons, designated persons, and their immediate relatives are advised not to trade in the securities during this period.

Parmax Pharma Limited reported a net loss of ₹4.16 crore for the financial year ended March 31, 2026, as revenue from operations declined to ₹12.12 crore. The company's Board of Directors approved the standalone audited financial results for the quarter and year ended March 31, 2026, during a meeting held on June 03, 2026. The statutory auditors, M/s. B A Shah S R Mehta & Co., Chartered Accountants, issued an unmodified opinion on the financial results.

Financial Performance

For the quarter ended March 31, 2026, the company recorded a net loss of ₹58.43 lakh on revenue from operations of ₹3.31 crore. In comparison, the net loss for the same period in the previous year was ₹1.49 crore on revenue of ₹4.83 crore. Total income for the quarter stood at ₹3.34 crore, down from ₹4.73 crore in the corresponding quarter of the previous year.

The company reported a loss before tax of ₹5.85 crore for the full year, compared to a loss of ₹2.40 crore in the previous year. Finance costs for the year increased to ₹12.40 crore, significantly impacting profitability. The basic earnings per share (EPS) for the year was negative at ₹11.12, compared to a negative EPS of ₹5.60 in the previous year.

Operational Highlights

Parmax Pharma operates in a single pharmaceutical segment. During the financial year, the company did not charge depreciation on its clean room plant and effluent treatment plant. Additionally, the company lodged an insurance claim wherein the surveyor provided an insurance provision amounting to ₹3.5 crore.

Assets and Liabilities

The company's total assets as of March 31, 2026, stood at ₹28.05 crore, an increase from ₹18.75 crore in the previous year. Current assets rose to ₹16.68 crore, driven by higher inventories and trade receivables. Total equity and liabilities increased to ₹28.05 crore, with current liabilities reaching ₹22.68 crore, primarily due to higher trade payables and other financial liabilities.

Cash Flow Statement

Cash flow from operating activities resulted in a net outflow of ₹2.36 crore during the year. The company utilized ₹90 lakh in investing activities, primarily for the purchase of fixed assets. Financing activities provided a net inflow of ₹3.81 crore, largely due to an increase in long-term borrowings. Cash and cash equivalents at the end of the year stood at ₹65 lakh, up from ₹9 lakh in the previous year.